Monday, December 23, 2024
HomeTagsAnti-tumor therapy

anti-tumor therapy

Akeso’s Ligufalimab and Ivonescimab Obtained Approval to Initiate a Phase II Trial

Akeso, Inc. announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics